Trial Profile
A retrospective study evaluating the clinical impact of crizotinib on brain metastases in patients with advanced ROS1-rearranged non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 11 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer